ACADIA PHARMACEUTICALS INC (ACAD) — insider trading
Health Care · NASDAQ
ACADIA PHARMACEUTICALS INC (ACAD) has 53 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 53 (latest 2026-08-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 14,292 | — | $0 | Form 4 |
| 2026-08-06 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | 9,292 | $29.34 | $272.6K | Form 4 |
| 2026-08-06 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | 5,000 | $29.00 | $145.0K | Form 4 |
| 2026-08-06 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 14,292 | $17.84 | $255.0K | Form 4 |
| 2026-08-05 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 5,849 | — | $0 | Form 4 |
| 2026-08-05 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | 5,849 | $29.00 | $169.6K | Form 4 |
| 2026-08-05 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 5,849 | $17.84 | $104.3K | Form 4 |
| 2026-07-30 | Thompson Elizabeth H.Z. | Officer (EVP, Head of Research & Dev) | Open-market sale | 50 | $26.17 | $1.3K | Form 4 |
| 2026-07-30 | Thompson Elizabeth H.Z. | Officer (EVP, Head of Research & Dev) | Open-market sale | 16,508 | $26.13 | $431.4K | Form 4 |
| 2026-07-29 | Thompson Elizabeth H.Z. | Officer (EVP, Head of Research & Dev) | Option exercise / conversion (derivative) | 32,272 | — | $0 | Form 4 |
| 2026-07-29 | Thompson Elizabeth H.Z. | Officer (EVP, Head of Research & Dev) | Option exercise / conversion | 32,272 | — | — | Form 4 |
| 2026-06-26 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Open-market sale | 11,421 | $26.08 | $297.9K | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting (derivative) | 32,008 | — | $0 | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting (derivative) | 32,008 | — | $0 | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting | 18,622 | — | $0 | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting | 18,622 | — | $0 | Form 4 |
| 2026-05-29 | Daly James M | Director | Grant / award / vesting (derivative) | 9,311 | — | $0 | Form 4 |
| 2026-05-29 | Daly James M | Director | Grant / award / vesting (derivative) | 16,004 | — | $0 | Form 4 |
| 2026-05-29 | Daly James M | Director | Option exercise / conversion (derivative) | 8,107 | — | $0 | Form 4 |
| 2026-05-29 | Daly James M | Director | Option exercise / conversion | 8,107 | — | — | Form 4 |
| 2026-05-29 | GAROFALO ELIZABETH A. | Director | Grant / award / vesting (derivative) | 9,311 | — | $0 | Form 4 |
| 2026-05-29 | GAROFALO ELIZABETH A. | Director | Grant / award / vesting (derivative) | 16,004 | — | $0 | Form 4 |
| 2026-05-29 | GAROFALO ELIZABETH A. | Director | Option exercise / conversion (derivative) | 8,107 | — | $0 | Form 4 |
| 2026-05-29 | GAROFALO ELIZABETH A. | Director | Option exercise / conversion | 8,107 | — | — | Form 4 |
| 2026-05-29 | Poole Jonathan | Director | Grant / award / vesting (derivative) | 9,311 | — | $0 | Form 4 |
| 2026-05-29 | Poole Jonathan | Director | Grant / award / vesting (derivative) | 16,004 | — | $0 | Form 4 |
| 2026-05-29 | Poole Jonathan | Director | Option exercise / conversion (derivative) | 2,010 | — | $0 | Form 4 |
| 2026-05-29 | Poole Jonathan | Director | Option exercise / conversion | 2,010 | — | — | Form 4 |
| 2026-05-29 | Brege Laura | Director | Grant / award / vesting (derivative) | 9,311 | — | $0 | Form 4 |
| 2026-05-29 | Brege Laura | Director | Grant / award / vesting (derivative) | 16,004 | — | $0 | Form 4 |
| 2026-05-29 | Brege Laura | Director | Option exercise / conversion (derivative) | 8,107 | — | $0 | Form 4 |
| 2026-05-29 | Brege Laura | Director | Option exercise / conversion | 8,107 | — | — | Form 4 |
| 2026-05-29 | Ndu Adora | Director | Grant / award / vesting (derivative) | 9,311 | — | $0 | Form 4 |
| 2026-05-29 | Ndu Adora | Director | Grant / award / vesting (derivative) | 16,004 | — | $0 | Form 4 |
| 2026-05-29 | Ndu Adora | Director | Option exercise / conversion (derivative) | 8,107 | — | $0 | Form 4 |
| 2026-05-29 | Ndu Adora | Director | Option exercise / conversion | 8,107 | — | — | Form 4 |
| 2026-05-29 | HARRIGAN EDMUND | Director | Grant / award / vesting (derivative) | 9,311 | — | $0 | Form 4 |
| 2026-05-29 | HARRIGAN EDMUND | Director | Grant / award / vesting (derivative) | 16,004 | — | $0 | Form 4 |
| 2026-05-29 | HARRIGAN EDMUND | Director | Option exercise / conversion (derivative) | 8,107 | — | $0 | Form 4 |
| 2026-05-29 | HARRIGAN EDMUND | Director | Option exercise / conversion | 8,107 | — | — | Form 4 |
| 2026-05-26 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Open-market sale | 5,401 | $21.18 | $114.4K | Form 4 |
| 2026-05-04 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | 3,506 | $21.79 | $76.4K | Form 4 |
| 2026-05-04 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Open-market sale | 1,332 | $21.79 | $29.0K | Form 4 |
| 2026-05-01 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 6,815 | — | $0 | Form 4 |
| 2026-05-01 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 6,815 | — | — | Form 4 |
| 2026-05-01 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Option exercise / conversion (derivative) | 2,596 | — | $0 | Form 4 |
| 2026-05-01 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Option exercise / conversion | 2,596 | — | — | Form 4 |
| 2026-04-07 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Open-market sale | 1,030 | $22.20 | $22.9K | Form 4 |
| 2026-04-07 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | 2,709 | $22.20 | $60.1K | Form 4 |
| 2026-04-05 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Option exercise / conversion (derivative) | 2,010 | — | $0 | Form 4 |
| 2026-04-05 | Kihara James | Officer (PRINCIPAL ACCOUNTING OFFICER) | Option exercise / conversion | 2,010 | — | — | Form 4 |
| 2026-04-05 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 5,276 | — | $0 | Form 4 |
| 2026-04-05 | Schneyer Mark C. | Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 5,276 | — | — | Form 4 |
Ask the chat about ACAD's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ACADIA PHARMACEUTICALS INC (ACAD).
Last updated 2026-08-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.